insights_auto
Why is ADAPY down 5.50%?
Dive Deeperchevron_right
ADAPY:OTCMKTS
Adaptimmune Therapeutics PLC - ADR
US$0.019
arrow_downward
-5.50%(-0.0011) 1D
ኖቬም 5, 4:00:00 ከሰዓት ጂ ኤም ቲ-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ADAPY...
Open
US$0.02
High
US$0.02
Low
US$0.02
Mkt. cap
5.01 ሚ
Avg. vol.
239.88 ሺ
Volume
826.35 ሺ
52-wk high
US$0.07
52-wk low
US$0.00
Beta
0.87
Shares outstanding
265.05 ሚ
No. of employees
272
Open
US$0.02
High
US$0.02
Low
US$0.02
Mkt. cap
5.01 ሚ
Avg. vol.
239.88 ሺ
Volume
826.35 ሺ
52-wk high
US$0.07
52-wk low
US$0.00
Beta
0.87
Shares outstanding
265.05 ሚ
No. of employees
272
News stories
From web sources and news partners
CNN
·
ከ1 ሰዓት በፊት
What sparked Wall Street’s crazy sell-off?
Business of Cannabis
·
ከ33 ደቂቃዎች በፊት
Brains Bioceutical To List On NASDAQ Via SPAC At US$750m Valuation
Yahoo Finance
·
ከ47 ደቂቃዎች በፊት
Invesco S&P 500 Equal Weight (RSP) Adds Okta and Moderna on Nov. 4
Reuters
·
ከ1 ሰዓት በፊት
Nasdaq futures rise after steep AI selloff as chip stocks stabilize
Profile
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park.
In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. In January 2025, the FDA granted breakthrough therapy designation to Adaptimmune's Letetresgene Autoleucel for Treatment of Myxoid/Round Cell Liposarcoma.
In July 2025, Adaptimmune announced their entry into a Definitive Agreement for Sale of Tecelra, lete-cel, and the pre-clinical uza-cel to US WorldMeds for $55M. Wikipedia
About Adaptimmune Therapeutics PLC - ADR
CEOAdrian Rawcliffe
Employees272
Founded2008
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteadaptimmune.com